Literature DB >> 22437252

Current treatment options for recurrent/metastatic head and neck cancer: a post-ASCO 2011 update and review of last year's literature.

T Kurzweg1, N Möckelmann, S Laban, R Knecht.   

Abstract

The majority of patients with a squamous cell carcinoma of the head and neck present with locally advanced tumors. The first-line treatment of locally advanced tumor stages consists of a combined modality management. Despite these aggressive protocols, many patients develop locoregional recurrences or metastasis and place particularly high demands on the interdisciplinary treatment team. Treatment with a curative intent must be differentiated from a palliative one. In addition to prior treatment, resectability, age and performance status, patient wishes must be taken into consideration in treatment planning, especially considering that most therapies offer little to no overall survival benefit. Salvage surgery, chemo- and target therapies, and reirradiation are head and neck surgeon's and radiooncologist's weapons in the fight against these strong opponents. This review focuses on publications and meeting news from last year and reviews the current status of the clinical application of each treatment modality in recurrent or metastatic head and neck cancer.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22437252     DOI: 10.1007/s00405-012-1998-3

Source DB:  PubMed          Journal:  Eur Arch Otorhinolaryngol        ISSN: 0937-4477            Impact factor:   2.503


  37 in total

Review 1.  Reirradiation in head and neck cancers.

Authors:  Francois Janot; Juliette Thariat; Nicolas Daly-Schweitzer
Journal:  Anticancer Drugs       Date:  2011-08       Impact factor: 2.248

2.  Novel neoadjuvant immunotherapy regimen safety and survival in head and neck squamous cell cancer.

Authors:  Gregory T Wolf; Willard E Fee; Robert W Dolan; Jeffrey S Moyer; Michael J Kaplan; Paul M Spring; James Suen; Daniel E Kenady; Jason G Newman; William R Carroll; M Boyd Gillespie; Scott M Freeman; Lorraine Baltzer; Terry D Kirkley; Harvey J Brandwein; John W Hadden
Journal:  Head Neck       Date:  2011-01-31       Impact factor: 3.147

3.  High-dose-rate intraoperative radiation therapy for recurrent head-and-neck cancer.

Authors:  David J Perry; Kelvin Chan; Suzanne Wolden; Michael J Zelefsky; Johnny Chiu; Gilad Cohen; Marco Zaider; Dennis Kraus; Jatin Shah; Nancy Lee
Journal:  Int J Radiat Oncol Biol Phys       Date:  2009-06-27       Impact factor: 7.038

4.  Prior chemoradiotherapy adversely impacts outcomes of recurrent and second primary head and neck cancer treated with concurrent chemotherapy and reirradiation.

Authors:  Kevin S Choe; Daniel J Haraf; Abhishek Solanki; Ezra E W Cohen; Tanguy Y Seiwert; Kerstin M Stenson; Elizabeth A Blair; Louis Portugal; Victoria M Villaflor; Mary Ellyn Witt; Everett E Vokes; Joseph K Salama
Journal:  Cancer       Date:  2011-06-13       Impact factor: 6.860

5.  Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.

Authors:  Jochen H Lorch; Olga Goloubeva; Robert I Haddad; Kevin Cullen; Nicholas Sarlis; Roy Tishler; Ming Tan; John Fasciano; Daniel E Sammartino; Marshall R Posner
Journal:  Lancet Oncol       Date:  2011-01-11       Impact factor: 41.316

6.  Initial results of a Phase I dose-escalation trial of concurrent and maintenance erlotinib and reirradiation for recurrent and new primary head-and-neck cancer.

Authors:  Kyle E Rusthoven; Steven J Feigenberg; David Raben; Madeleine Kane; John I Song; Nicos Nicolaou; Ranee Mehra; Barbara Burtness; John Ridge; Robyn Swing; Miriam Lango; Roger Cohen; Antonio Jimeno; Changhu Chen
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-03-16       Impact factor: 7.038

7.  Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: a Southwest Oncology Group study.

Authors:  A A Forastiere; B Metch; D E Schuller; J F Ensley; L F Hutchins; P Triozzi; J A Kish; S McClure; E VonFeldt; S K Williamson
Journal:  J Clin Oncol       Date:  1992-08       Impact factor: 44.544

8.  Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial.

Authors:  Jaffer A Ajani; Wuilbert Rodriguez; Gyorgy Bodoky; Vladimir Moiseyenko; Mikhail Lichinitser; Vera Gorbunova; Ihor Vynnychenko; August Garin; Istvan Lang; Silvia Falcon
Journal:  J Clin Oncol       Date:  2010-02-16       Impact factor: 44.544

Review 9.  Cetuximab for the treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck.

Authors:  J Greenhalgh; A Bagust; A Boland; N Fleeman; C McLeod; Y Dundar; C Proudlove; R Shaw
Journal:  Health Technol Assess       Date:  2009-10       Impact factor: 4.014

10.  Phase I/II trial of cilengitide with cetuximab, cisplatin and 5-fluorouracil in recurrent and/or metastatic squamous cell cancer of the head and neck: findings of the phase I part.

Authors:  J B Vermorken; J Guigay; R Mesia; J M Trigo; U Keilholz; A Kerber; U Bethe; M Picard; T H Brummendorf
Journal:  Br J Cancer       Date:  2011-05-03       Impact factor: 7.640

View more
  10 in total

1.  The Ah receptor regulates growth factor expression in head and neck squamous cell carcinoma cell lines.

Authors:  Kaarthik John; Tejas S Lahoti; Kelly Wagner; Jarod M Hughes; Gary H Perdew
Journal:  Mol Carcinog       Date:  2013-04-27       Impact factor: 4.784

2.  Palliative treatment standards for head and neck squamous cell carcinoma : Survey of clinical routine in German-speaking countries.

Authors:  S Laban; J Kimmeyer; R Knecht; T K Hoffmann; C-J Busch; J A Veit; N Möckelmann; T Kurzweg
Journal:  HNO       Date:  2016-07       Impact factor: 1.284

3.  Benzyl isothiocyanate inhibits HNSCC cell migration and invasion, and sensitizes HNSCC cells to cisplatin.

Authors:  M Allison Wolf; Pier Paolo Claudio
Journal:  Nutr Cancer       Date:  2014-01-21       Impact factor: 2.900

Review 4.  Post-therapeutic surveillance strategies in head and neck squamous cell carcinoma.

Authors:  Antoine Digonnet; Marc Hamoir; Guy Andry; Missak Haigentz; Robert P Takes; Carl E Silver; Dana M Hartl; Primož Strojan; Alessandra Rinaldo; Remco de Bree; Andreas Dietz; Vincent Grégoire; Vinidh Paleri; Johannes A Langendijk; Vincent Vander Poorten; Michael L Hinni; Juan P Rodrigo; Carlos Suárez; William M Mendenhall; Jochen A Werner; Eric M Genden; Alfio Ferlito
Journal:  Eur Arch Otorhinolaryngol       Date:  2012-09-13       Impact factor: 2.503

5.  Use of inpatient palliative care services in patients with metastatic incurable head and neck cancer.

Authors:  Carolyn L Mulvey; Thomas J Smith; Christine G Gourin
Journal:  Head Neck       Date:  2015-06-16       Impact factor: 3.147

6.  [Therapy of recurrent or metastatic head and neck squamous cell carcinoma : highlights of the ASCO Meeting 2014].

Authors:  N Zeller; C-J Busch; P Schafhausen; R Knecht; N Möckelmann
Journal:  HNO       Date:  2014-11       Impact factor: 1.284

7.  FDG volumetric parameters and survival outcomes after definitive chemoradiotherapy in patients with recurrent head and neck squamous cell carcinoma.

Authors:  Vasavi Paidpally; Alin Chirindel; Christine H Chung; Jeremy Richmon; Wayne Koch; Harry Quon; Rathan M Subramaniam
Journal:  AJR Am J Roentgenol       Date:  2014-08       Impact factor: 3.959

8.  Multicenter research into the quality of life of patients with advanced oropharyngeal carcinoma with long-term survival associated with human papilloma virus.

Authors:  Giacomo Spinato; Marco Stellin; Giuseppe Azzarello; Deborah Bonazza; Fabrizio Zanconati; Doriano Politi; Salvatore Cocuzza; Paola Di Mauro; Simonetta Ausoni; Giovanni Tonoli; Giulio Costantini; Luigi Maiolino; Roberto Spinato; Maria Cristina Da Mosto; Lorena Baboci; Annarosa Del Mistro; Agostino Serra; Giancarlo Tirelli
Journal:  Oncol Lett       Date:  2017-05-10       Impact factor: 2.967

9.  Photobiomodulation therapy in management of cancer therapy-induced side effects: WALT position paper 2022.

Authors:  Jolien Robijns; Raj G Nair; Joy Lodewijckx; Praveen Arany; Andrei Barasch; Jan M Bjordal; Paolo Bossi; Anne Chilles; Patricia M Corby; Joel B Epstein; Sharon Elad; Reza Fekrazad; Eduardo Rodrigues Fregnani; Marie-Thérèse Genot; Ana M C Ibarra; Michael R Hamblin; Vladimir Heiskanen; Ken Hu; Jean Klastersky; Rajesh Lalla; Sofia Latifian; Arun Maiya; Jeroen Mebis; Cesar A Migliorati; Dan M J Milstein; Barbara Murphy; Judith E Raber-Durlacher; Hendrik J Roseboom; Stephen Sonis; Nathaniel Treister; Yehuda Zadik; René-Jean Bensadoun
Journal:  Front Oncol       Date:  2022-08-30       Impact factor: 5.738

10.  Cisplatin/Tegafur/Uracil/Irinotecan Triple Combination Therapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma: A Phase I/II Clinical Study.

Authors:  San-Chi Chen; Peter Mu-Hsin Chang; Muh-Hwa Yang
Journal:  Oncologist       Date:  2016-04-18
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.